$8.79
Today
as of Sep 4, 16:50 ET
Last 30 days
Recent Press Releases & News
Iovance Biotherapeutics to Present at Upcoming Conferences
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Overview
52-week range
$1.76
$9.36
93% of range
Avg surprise (last 3)
-19.3%
Avg reaction (last 2)
-6.0%
50% positive
Latest IV / EM
179%
EM ±7.5% · $9 · Sep 4
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.11 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-0.19 | $-0.19 | 0.0% | +47.2% | -13.2% | earnings |
| Thu Aug 7, 2025 | Jun/2025 | $-0.33 | $-0.29 | -13.8% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.36 | $-0.25 | -44.0% | — | +1.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.28 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.34 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.42 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.46 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.47 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.50 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $99M | $71M | — | $67M | $60M | $49M | — | $59M |
| Cost of revenue | $44M | $42M | — | $38M | $49M | $43M | — | $32M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-52M | $-81M | — | $-95M | $-114M | $-121M | — | $-89M |
| Net income | $-47M | $-79M | — | $-91M | $-112M | $-116M | — | $-84M |
| EPS (diluted) | $-0.11 | $-0.19 | — | — | $-0.33 | $-0.36 | — | $-0.28 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $111M | $197M | $163M | $158M | $132M | $172M | $116M | $164M |
| Inventory | $56M | $58M | $52M | $52M | $50M | $66M | $52M | $39M |
| Total current assets | $464M | $467M | $443M | $429M | $422M | $513M | $457M | $499M |
| Total assets | $916M | $926M | $913M | $905M | $907M | $967M | $910M | $991M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $179M | $204M | $215M | $203M | $209M | $199M | $200M | $218M |
| Total equity | $736M | $722M | $699M | $702M | $698M | $768M | $710M | $773M |